 |
12 Diseases |  |
4 Trials |
|
4 Trials |  |
312 News |  |
| «12345» |
- ||| Fumaderm (dimethyl fumarate) / Biogen
P3 data, Retrospective data, Journal: Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies. (Pubmed Central) - Apr 5, 2022
The lower rate of whole brain volume loss with DMF in this pooled BPF analysis in the second year vs. PBO is consistent with its effects on relapses, disability, and MRI lesions. Brain volume changes in the first year may be explained by pseudoatrophy effects also described in other MS clinical trials.
- || Tysabri (natalizumab) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal, HEOR: Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. (Pubmed Central) - Mar 26, 2022
Brain volume changes in the first year may be explained by pseudoatrophy effects also described in other MS clinical trials. This novel real-world analysis suggests a clinical benefit for therapy escalation to natalizumab versus fingolimod based on comparative effectiveness results, translating to higher QALYs and lower costs for UK patients inadequately responding to BRACETD.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. (Pubmed Central) - Mar 12, 2022
P=N/A
Interim results from this large registry indicate that early DMF exposure was not significantly associated with adverse pregnancy outcomes. Outcomes are consistent with previous smaller reports and with the general population.
- Temporal Trends in Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated With Natalizumab, Ocrelizumab or Fumarates (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3888;
T-cell responses were comparable among all three treatment cohorts. Two months after the second vaccine, the serological responses decreased by 45-79%.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Updated Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3763;
Two months after the second vaccine, the serological responses decreased by 45-79%. In this analysis of >1,000 patients treated with DRF in real-world clinical practice, overall persistence at 16 months was high, treatment discontinuation due to GI AEs was low, and patients were highly adherent to therapy. Study Supported by: Biogen
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Diroximel Fumarate (DRF) Has High Rates of Real-World Adherence and Persistence in Patients with Multiple Sclerosis (MS): Retrospective Claims Analysis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3761;
Adherence rates were high throughout time on treatment for patients on DRF. Outcomes for DRF are consistent with or higher than those for other DMTs observed in the same treatment period.Study Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
Retrospective Evaluation of De-Escalation from Anti-CD20 Therapies to Fumarates as a Treatment Approach (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3751;
Patients had a variety of motivations for switching to DMF from anti-CD20s. Additional patients will be presented.
- Fumaderm (dimethyl fumarate) / Biogen
Dimethyl Fumarate Demonstrates Treatment Effectiveness in Patients One Year After Switching From Teriflunomide (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3750;
P=N/A, P4
DMF is an effective therapeutic strategy for patients previously treated with teriflunomide regardless of if switching for efficacy or non-efficacy reasons. Study Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3614;
P=N/A
Results from the 6-year interim analysis demonstrate the safety profile in this ongoing, real-world observational study is consistent with the known profile of DMF. Similarly, relapse rates were low and both ARR and PROs remained stable over time indicating sustained effectiveness for patients who remain on DMF treatment over 6 years.Support:Biogen
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3610;
P3
At 2 years, safety, clinical, and radiological measures were reduced from baseline, supporting DRF as an effective treatment option and consistent with the known benefit-risk profile for DMF. The low rate of treatment discontinuation over 2 years suggests DRF is a well-tolerated treatment option for RRMS.Study Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
Predicting Treatment Response with MRI-Based Subtyping in Relapsing and Secondary Progressive MS (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3001;
NTZ and DMF reduced inflammatory disease activity in all SuStaIn subtypes with no significant differences in treatment response. SuStaIn MS subtyping did not discriminate responder heterogeneity as assessed by new lesion formation in these NTZ and DMF trials.
- || Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic-Therapy-Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial. (Pubmed Central) - Mar 4, 2022
Risankizumab was found superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favorable safety results consistent with the known safety profile. No new safety signals for risankizumab or FAEs were observed.
- Fumaderm (dimethyl fumarate) / Biogen
Cognitive Function in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate: 3-Year Longitudinal Analysis (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_405;
Cognitive function was maintained from baseline regardless of previous DMT treatment history. Maintaining longitudinal multi-domain cognitive NEDA provides additional DMT value.
- Fumaderm (dimethyl fumarate) / Biogen
Single Cell Transcriptomic and Epigenetic Biomarkers of Multiple Sclerosis in an Underrepresented Minority Population (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_175;
Combinatorial analysis of methylomics and single cell transcriptomics revealed additional gene-specific associations of MS with myeloid cells. These results may be of specific relevance in the regulation of disease susceptibility and severity in African American patients.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. (Pubmed Central) - Jan 18, 2022
Most US NARCOMS Registry participants treated up to 5 years with DMF remained free from 6-month confirmed disability progression and conversion to secondary progressive MS and had stable disability and employment status. These results support the long-term stability of disability and work-related outcomes with disease-modifying therapy.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal, Real-world evidence: Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. (Pubmed Central) - Jan 14, 2022
In this study, DMF and FTY demonstrated similar effects on physical and cognitive neuroperformance and MRI outcomes. Direct comparisons to other fumarates and S1P receptor modulators were not conducted.
- Fumaderm (dimethyl fumarate) / Biogen, Ocrevus (ocrelizumab) / Roche, Biogen
[VIRTUAL] Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab () - Nov 20, 2021 - Abstract #CMSC2021CMSC_681;
DMF-treated patients matched with OCR patients experienced lower annualized rates of infection encounters and lower infection-related healthcare costs. Study Support: Biogen
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses. (Pubmed Central) - Oct 30, 2021
Fumaric acid esters exhibit different biodistribution and may elicit different biological responses; furthermore, pharmacodynamic effects of combinations differ unpredictably from monotherapy. The strong potential to induce lymphopenia in patients with MS may be a result of activation of apoptosis pathways by MEF compared with DMF.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal, Heterogeneity: A two-stage prediction model for heterogeneous effects of treatments. (Pubmed Central) - Oct 27, 2021
We apply the approach to a network meta-analysis of three randomized clinical trials comparing the relapses in Natalizumab, Glatiramer Acetate, and Dimethyl Fumarate, including 3590 patients diagnosed with relapsing-remitting multiple sclerosis...For high-risk patients, the treatment that minimizes the risk of relapse in 2 years is Natalizumab, whereas Dimethyl Fumarate might be a better option for low-risk patients. Our approach can be easily extended to all outcomes of interest and has the potential to inform a personalized treatment approach.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study () - Oct 8, 2021 - Abstract #CMSC2021CMSC_664;
The DRF EXPERIENCEUS Phase 4 study will characterize treatment persistence, safety, and clinical effectiveness of DRF in routine clinical practice. Study Support: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem () - Oct 8, 2021 - Abstract #CMSC2021CMSC_629;
P=N/A
Results from the 5-year analysis reveal no new safety concerns emerging from the use of DMF in MS patients treated with DMF in the real-world setting. ARR at 5 years was significantly reduced vs. the year prior to DMF initiation.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data () - Oct 8, 2021 - Abstract #CMSC2021CMSC_607;
In particular, quantitative image analysis may be hampered by suboptimal protocols in terms of slice thickness and inconsistency in terms of imaging protocols over time. Despite these challenges, the study shows that atrophy values as detected from DMF-treated subjects in the real world follow those of randomized controlled trials.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Combinatorial Analysis of Plasma and DNA Methylation Biomarkers in African American Patients with Multiple Sclerosis () - Oct 8, 2021 - Abstract #CMSC2021CMSC_497;
Younger African American MS patients have higher age-adjusted NFL levels as compared to age-matched controls. In addition, different patterns of DNA methylation in peripheral immune cells were observed in MS patients and control donors with elevated NFL values.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies () - Oct 8, 2021 - Abstract #CMSC2021CMSC_462;
HCP-reported reasons for selecting DRF included good tolerability profile, oral dosing, mechanism of action and reduction in relapses. Two-thirds of HCPs perceived DRF to have a better GI tolerability profile compared to DMF.
- [VIRTUAL] COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy (GATLIN A3/A4) - Oct 8, 2021 - Abstract #CMSC2021CMSC_117;
This prospective open-label observational study is recruiting 120 participants (natalizumab [NTZ] n=30, ocrelizumab [OCR] n=30, fumarate [FUM] (dimethyl fumarate [DMF] or diroximel fumarate [DRF] n=30), and interferon [IFN, any IFN and peginterferon beta-1a] n=30) ages 18 65 years inclusive, with a diagnosis of relapsing MS who are stable on their current DMT for >6 months... This study will provide healthcare practitioners with additional quantitative data on the humoral immune response to mRNA-1273 COVID-19 vaccination in MS patients treated by various DMTs.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Low-dose, long-term fumaric acid esters in recalcitrant cutaneous sarcoidosis : Report of two cases (Pubmed Central) - Sep 29, 2021
We have reported that successful treatment of the skin lesions of a patient with recalcitrant systemic sarcoidosis with Fumaderm® (Biogen, Munich, Germany; 360-720 mg/day dimethyl fumarate) had to be discontinued due to the development of lymphocytopenia. Therefore, we treated two further patients with the low-dose Fumaderm® Initial (90 mg/day dimethyl fumarate) and observed a partial remission of the skin lesions over a minimum 18 month follow-up without signs of lymphocytopenia.
- ||| Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Clinical, P3 data, P3 data: top line, Journal: Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. (Pubmed Central) - Sep 26, 2021
At Week 48, mean number of gadolinium-enhancing lesions was significantly reduced from baseline (77%; p < 0.0001) and adjusted annualized relapse rate was low (0.16; 95% confidence interval: 0.13-0.20). Interim data from EVOLVE-MS-1 suggest DRF is a well-tolerated treatment with a favorable safety/efficacy profile for patients with RRMS.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. (Pubmed Central) - Sep 26, 2021
No increase in infection incidence was observed in patients with or without lymphopenia. Biogen.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 Study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2608;
P3
The low rate of treatment discontinuation over the 2-year period suggests DRF is a well-tolerated treatment option for RRMS. At 2 years, clinical and radiological measures were reduced from baseline, supporting DRF as an effective treatment option.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Early data suggests diroximel fumarate has high rates of real-world adherence and persistence (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2390;
The finding that higher persistence is seen with newer DMTs vs older DMTs should be explored in future matched comparisons. These data support DRF as a well-tolerated fumarate.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Multiple sclerosis patients treated with diroximel fumarate over 1 year in the real-world setting have high rates of persistence and adherence (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2378;
Adherence was also high in the prior DMF subgroup. The most common reason for discontinuing prior DMF was GI AEs; most of the prior DMF pts were able to remain on DRF, further supporting improved GI tolerability with DRF.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Dimethyl fumarate and fingolimod utilization and costs for multiple sclerosis: a population-based study in the Campania Region of Italy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2340;
DMF and fingolimod were used in similar populations (age, disability). While there were no differences in efficacy (i.e., treatment escalation), DMF was associated with higher adherence, lower treatment costs, lower hospital admissions’ rates and costs.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2261;
GI AE incidence/severity were highest with DMF in Weeks 3 and 4, after the 1-week titration. This is consistent with DMF real-world experience, where some HCPs have employed extended titration schedules to improve GI tolerability.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis: results from the Phase 3 EVOLVE-MS-2 Study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2243;
P3
Although in DRF-treated patients flushing occurred in fewer patients, the incidence of flushing for DRF was generally within the expected range when compared to rates reported in DMF controlled clinical trials. The clinical meaningfulness of the observed changes is uncertain and additional real-world studies are necessary.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Circulating microRNAs in RRMS patients treated with dimethyl fumarate in the phase 4 TREMEND trial (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2149;
Altered expression peaked after 6 months. This may either reflect mechanisms of DMF or change in MS disease-related pathways.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] q -Space myelin map imaging for longitudinal analysis of remyelination in multiple sclerosis patients treated with dimethyl fumarate, follow-up results (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2021;
The updated report implies that DMF has the efficacy of remyelination not only in the early phase of DMF treatment. We continue this study to investigate the association between q MM-supported remyelination and disease progression.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Disease activity and patient-reported outcomes in patients with multiple sclerosis switching from first-line platform therapies to dimethyl fumarate (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1847;
P=N/A
Overall, results suggest that DMF is an effective treatment option for patients with RRMS previously treated with injectable therapies or teriflunomide, regardless of the reasons that led to the switch from the previous first-line treatment. Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Pregnancy outcomes following exposure to dimethyl fumarate: interim analysis of a prospective international registry (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1739;
P=N/A
Outcomes are consistent with previous smaller reports and with the general population. Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] CONNECT: an open-label, active-controlled dimethyl fumarate study in pediatric patients with relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1646;
P3
Adjusted ARR also was lower for DMF vs IFNβ-1a at W96. Overall safety and tolerability in pediatric patients were consistent with the adult population.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. (Pubmed Central) - Sep 22, 2021
The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.
- opicinumab (BIIB033) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Efficacy and safety of opicinumab in participants with relapsing multiple sclerosis: a randomized, placebo-controlled, Phase 2 trial (AFFINITY Part 1) (Stream 7 Therapy / Global views) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1287;
P2
Learnings from the AFFINITY study and additional data analyses may inform the design of future remyelination trials. Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 Study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1058;
P3
The low rate of treatment discontinuation over the 2-year period suggests DRF is a well-tolerated treatment option for RRMS. At 2 years, clinical and radiological measures were reduced from baseline, supporting DRF as an effective treatment option.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Disease activity and patient-reported outcomes in patients with multiple sclerosis switching from first-line platform therapies to dimethyl fumarate (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1037;
P=N/A
Overall, results suggest that DMF is an effective treatment option for patients with RRMS previously treated with injectable therapies or teriflunomide, regardless of the reasons that led to the switch from the previous first-line treatment. Supported by: Biogen
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_916;
GI AE incidence/severity were highest with DMF in Weeks 3 and 4, after the 1-week titration. This is consistent with DMF real-world experience, where some HCPs have employed extended titration schedules to improve GI tolerability.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis: results from the Phase 3 EVOLVE-MS-2 Study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_897;
P3
Although in DRF-treated patients flushing occurred in fewer patients, the incidence of flushing for DRF was generally within the expected range when compared to rates reported in DMF controlled clinical trials. The clinical meaningfulness of the observed changes is uncertain and additional real-world studies are necessary.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Early data suggests diroximel fumarate has high rates of real-world adherence and persistence (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_771;
The finding that higher persistence is seen with newer DMTs vs older DMTs should be explored in future matched comparisons. These data support DRF as a well-tolerated fumarate.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Multiple sclerosis patients treated with diroximel fumarate over 1 year in the real-world setting have high rates of persistence and adherence (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_759;
Adherence was also high in the prior DMF subgroup. The most common reason for discontinuing prior DMF was GI AEs; most of the prior DMF pts were able to remain on DRF, further supporting improved GI tolerability with DRF.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] q -Space myelin map imaging for longitudinal analysis of remyelination in multiple sclerosis patients treated with dimethyl fumarate, follow-up results (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_599;
The updated report implies that DMF has the efficacy of remyelination not only in the early phase of DMF treatment. We continue this study to investigate the association between q MM-supported remyelination and disease progression.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Pregnancy outcomes following exposure to dimethyl fumarate: interim analysis of a prospective international registry (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_352;
P=N/A
Outcomes are consistent with previous smaller reports and with the general population. Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Circulating microRNAs in RRMS patients treated with dimethyl fumarate in the phase 4 TREMEND trial (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_281;
Altered expression peaked after 6 months. This may either reflect mechanisms of DMF or change in MS disease-related pathways.